Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
